Cargando…

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

OBJECTIVES: Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bénard, Angèle, Chouinard, Sylvain, Leavitt, Blair R, Budd, Nathalie, Wu, Jennifer W, Schoffer, Kerrie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161103/ https://www.ncbi.nlm.nih.gov/pubmed/35649593 http://dx.doi.org/10.1136/bmjopen-2022-062740

Ejemplares similares

Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects
por: Abreu, Daisy, et al.
Publicado: (2021)

International Guidelines for the Treatment of Huntington's Disease
por: Bachoud-Lévi, Anne-Catherine, et al.
Publicado: (2019)

Is Ataxia an Underestimated Symptom of Huntington's Disease?
por: Franklin, Gustavo L., et al.
Publicado: (2020)

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease
por: Stout, Julie C, et al.
Publicado: (2012)

Preface to the Special Issue on “Sleep and Circadian Disorder in Huntington’s Disease”
por: Leavitt, Blair R., et al.
Publicado: (2023)

Targeting Tau to Treat Clinical Features of Huntington's Disease
por: Masnata, Maria, et al.
Publicado: (2020)

Mild Cognitive Impairment as an Early Landmark in Huntington's Disease
por: Zhang, Ying, et al.
Publicado: (2021)

Case report: Cerebellar sparing in juvenile Huntington's disease
por: Santos-Lobato, Bruno Lopes, et al.
Publicado: (2023)

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
por: Mazarei, Gelareh, et al.
Publicado: (2015)

DNA Methylation Profiles in Whole Blood of Huntington's Disease Patients
por: Zadel, Maja, et al.
Publicado: (2018)

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?
por: Migliore, Simone, et al.
Publicado: (2019)

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review
por: Kinnunen, Kirsi M., et al.
Publicado: (2021)

Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia
por: Saba, Julieta, et al.
Publicado: (2022)

Platelet abnormalities in Huntington’s disease
por: Denis, Hélèna L, et al.
Publicado: (2019)

Ranking the Predictive Power of Clinical and Biological Features Associated With Disease Progression in Huntington's Disease
por: Ghazaleh, Naghmeh, et al.
Publicado: (2021)

Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials
por: Kinnunen, Kirsi M., et al.
Publicado: (2021)

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington’s Disease
por: Mansoor, Nina M., et al.
Publicado: (2021)

Prevalence of neurocognitive disorder in Huntington’s disease using the Enroll-HD dataset
por: Sierra, Luis A., et al.
Publicado: (2023)

Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
por: Heinzel, Sebastian, et al.
Publicado: (2018)

Need for personalized monitoring of Parkinson’s disease: the perspectives of patients and specialized healthcare providers
por: Evers, Luc J. W., et al.
Publicado: (2023)

Gender Differences in Non-sex Linked Disorders: Insights From Huntington's Disease
por: Zielonka, Daniel, et al.
Publicado: (2020)

Juvenile Huntington’s Disease: A Case Report and a Review of Diagnostic Challenges
por: Yu, Su-Yuan, et al.
Publicado: (2023)

Longitudinal expression changes are weak correlates of disease progression in Huntington’s disease
por: Mitchell, Christopher T, et al.
Publicado: (2020)

Health-related quality of life and unmet healthcare needs in Huntington’s disease
por: van Walsem, Marleen R., et al.
Publicado: (2017)

Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease
por: Sathe, Swati, et al.
Publicado: (2021)

Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease
por: You, Huajing, et al.
Publicado: (2021)

Combining Literature Review With a Ground Truth Approach for Diagnosing Huntington's Disease Phenocopy
por: Nguyen, Quang Tuan Rémy, et al.
Publicado: (2022)

Treatment of Irritability in Huntington’s Disease
por: van Duijn, Erik
Publicado: (2010)

The Clinical Picture of Psychosis in Manifest Huntington's Disease: A Comprehensive Analysis of the Enroll-HD Database
por: Rocha, Natalia P., et al.
Publicado: (2018)

Corrigendum: Combining Literature Review With a Ground Truth Approach for Diagnosing Huntington's Disease Phenocopy
por: Nguyen, Quang Tuan Rémy, et al.
Publicado: (2022)

Aberrant resting-state brain activity in Huntington's disease: A voxel-based meta-analysis
por: Zhang, Sirui, et al.
Publicado: (2023)

Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach
por: Ko, Jinnie, et al.
Publicado: (2023)

Magnetic resonance imaging of Huntington's disease: preparing for clinical trials
por: Klöppel, S., et al.
Publicado: (2009)

The sleep and circadian problems of Huntington’s disease: when, why and their importance
por: Voysey, Z., et al.
Publicado: (2020)

Potential biomarkers to follow the progression and treatment response of Huntington’s disease
por: Disatnik, Marie-Hélène, et al.
Publicado: (2016)

A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice
por: Heath, Christopher J., et al.
Publicado: (2019)

RNA Sequencing of Human Peripheral Blood Cells Indicates Upregulation of Immune-Related Genes in Huntington's Disease
por: Andrade-Navarro, Miguel A., et al.
Publicado: (2020)

Quantification of Daily-Living Gait Quantity and Quality Using a Wrist-Worn Accelerometer in Huntington's Disease
por: Keren, Karin, et al.
Publicado: (2021)

Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study
por: Ferraldeschi, Michela, et al.
Publicado: (2021)

Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington’s Disease–associated Chorea Initiated on Tetrabenazine
por: Sung, Victor W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ovndfiire2bbo2qp2coqn28jdb